Pharmaceutical

Astellas seeks approval for Padcev-Keytruda combo therapy in Japan

Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.

Jan 31, 2024 - 18:00
Astellas seeks approval for Padcev-Keytruda combo therapy in Japan
Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.
Read the original article

Tags:

Previous Article

Can Musk’s BCI company Neuralink be trusted to put chips in your brain?

Next Article

Major trial testing shows a reduction in pain by using Vertex’s non-opioid medic...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Doudna talks cost, access issues looming over first CRISPR therapy

STAT+: Doudna talks cost, access issues looming over fi...

May 5, 2023

Chiesi partners with Haisco to commercialise bronchiectasis drug  

Chiesi partners with Haisco to commercialise bronchiect...

Nov 20, 2023

STAT+: Pharmalittle: FDA panel to review Alzheimer’s treatment; FDA advisers back approval of RSV drug for children

STAT+: Pharmalittle: FDA panel to review Alzheimer’s tr...

Jun 10, 2023